361 Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-29,686
Closed -$1.27M 286
2019
Q4
$1.27M Sell
29,686
-32,829
-53% -$1.43M 0.35% 135
2019
Q3
$2.25M Buy
+62,515
New +$1.9M 0.42% 135

Other funds holding ACAD

361 Capital's ACAD Position: Q1 2020 in Review

361 Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 29,686 shares — an estimated $1.27M sold.

361 Capital first reported a position in ACAD in Q3 2019 and held it in 2 quarters. The position peaked at $2.25M in Q3 2019. 246 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

  • 361 Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • 361 Capital sold 29,686 Acadia Pharmaceuticals shares in Q1 2020, an estimated $1.27M.
  • 361 Capital first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • 361 Capital's Acadia Pharmaceuticals position peaked at $2.25M in Q3 2019.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.